Antituberculosis therapy for 2012 and beyond

作者：Lauzardo Michael; Peloquin Charles A^*

来源：Expert Opinion on Pharmacotherapy, 2012, 13(4): 511-526.

DOI：10.1517/14656566.2012.657176

• tuberculosis
• multidrug resistant tuberculosis
• rifampin
• rifapentine
• TMC207
• PA 824
• OPC-67683
• SQ109
• PNU-100480
• AZD-5847
• moxifloxacin
• levofloxacin

Introduction: In terms of human suffering, tuberculosis has a huge impact on global society, making it arguably the most important infectious disease in history. Despite the devastating impact on society, the tools to fight tuberculosis are very limited. Current standard therapy has been used for over 40 years and threats, such as the HIV epidemic and drug-resistant strains, undermine efforts to control the disease. New drugs are needed to address the challenges faced globally.
Areas covered: Current therapy is briefly reviewed in this paper and then new doses and combinations of existing drugs are presented. New candidate drugs are also discussed, along with the potential benefits and pitfalls of each of the compounds and approaches to therapy.
Expert opinion: Despite the need to develop new drugs, the ability of programs to deliver existing therapies must not be neglected. Directly observed therapy and a standard basic level of care for all patients with tuberculosis, regardless of where they reside, is imperative, and will ensure that new drugs and regimens will have the greatest possible impact. New combination regimens, including PA 824 and TMC207, in combination with existing drugs, are very exciting - not only because of their ability to shorten treatment regimens in pan-susceptible cases, but also because they can be used among drug-resistant strains. Although an effective vaccine will probably be necessary to eliminate tuberculosis, new drugs and combination regimens have the potential to save millions of lives before tuberculosis is finally eliminated.

• 出版日期2012-3